Navigation Links
Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer's Disease
Date:12/16/2008

Research Uncovers New Link Between Inflammation & Alzheimer's Disease

SARASOTA, Fla., Dec. 16 /PRNewswire/ -- The Roskamp Institute today announced that its researchers have uncovered a new link between inflammation and Alzheimer's disease and have identified a potential target for developing novel therapeutics for intervention in this disease. The study, led by Roskamp Institute's Pancham Bakshi, Ph.D., is detailed in the American Chemical Society's Chemical Biology Journal, a leading online publisher of peer-reviewed research.

It has long been known that Alzheimer's disease is accompanied by inflammation, which both exacerbates and is caused by the underlying disease. In addition, it has long been suggested that abnormal deposits of a small protein, known as amyloid, which accumulate in the brain of those afflicted by Alzheimer's disease, also trigger an inflammatory response. This inflammatory response is thought to be detrimental to nerve cells, eventually causing their destruction.

Recent research at the Roskamp Institute has revealed that inflammation can lead to the production of more amyloid, and researchers have found that a specific receptor on the nerve cell surface, known as CXCR2, is an interface between inflammation and new amyloid production. As specific inflammatory molecules contact CXCR2, a signal is generated which results in increased amyloid production. The presence of the abnormally occurring amyloid; therefore, contributes to its own reproduction through the inflammatory response it triggers.

"I found that by genetically knocking out CXCR2, we can reduce the amount of amyloid in various laboratory models and, by using drugs that specifically block the CXCR2 receptor, we are able to show that a decrease in production of amyloid can be achieved," said Dr. Bakshi. "This study, which for the first time shows the early role of inflammation in AD, opens a new door for therapeutic intervention, potentially leading to the use of CXCR2 blocking agents as a way to treat both the inflammation and the amyloid production in Alzheimer's disease."

"Finding new classes of medications for Alzheimer's disease is a world-wide priority," said Michael Mullan, M.B.B.S., Ph.D., director of the Roskamp Institute. "Dr. Bakshi's work highlights a new class of drugs that should have the benefit of both stopping inflammation and, importantly, stopping the accumulation of the pathologic amyloid. In addition to the drug Dr. Bakshi has already tested, she is making her own drugs to attack this potentially important target."

Dr. Bakshi is currently a scientist II in the Roskamp Institute and leads the Laboratory of Chemical Biology and Drug Discovery in Neurology. Prior to the Roskamp Institute, Dr. Bakshi was a postdoctoral researcher with Dr. Michael Wolfe at Harvard Medical School, Center for Neurology from 2001-2004 and a sabbatical postdoctoral fellow at Harvard Medical School, Laboratory of Drug Discovery in Neurology with Dr. Michael Wolfe and Dr. Ross Stein from 2002-2003. Dr. Bakshi has a Ph.D. in Bioorganic Chemistry from the Center for Biochemical Technology, New Delhi, and a Master of Science in Organic Chemistry and Bachelor of Science in Chemistry from the University of Delhi, New Delhi.

The Roskamp Institute is a not-for-profit research Institute located in Manatee County and Hillsborough County, Florida, that is dedicated to understanding the causes of, and finding cures for, neuropsychiatric and neurodegenerative disorders and addictions with an emphasis on Alzheimer's disease. The Roskamp Institute's Memory Centers also offer comprehensive cognitive and medical assessment toward differential diagnosis of Alzheimer's disease and offers treatments and disease management options once the diagnostic evaluation is complete.

For more information regarding Dr. Bakshi's findings or the Roskamp Institute's continued research, please contact the Roskamp Institute in Manatee County at (941) 752-2949, the Roskamp Institute Clinical Trials Division in Manatee County at (941) 752-2949, the Roskamp Institute Memory Center in Hillsborough County at (813) 979-2008 or visit us online at www.RoskampInstitute.com.


'/>"/>
SOURCE The Roskamp Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
2. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
3. Open Letter to President-Elect Barack Obama From Don Margolis, Chairman and Founder of The Repair Stem Cell Institute
4. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
5. Texas Back Institute Leads Way in New Facet Joint Clinical Trial
6. Sarah Cannon Research Institute Selects OmniComm Systems Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management
7. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
8. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
9. Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study
10. Agendias MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
11. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, Inc. ... providing the Urology, Uro/Gyn and Gynecology markets with innovative ... first quarter ended March 31, 2017 after the market ... The Company will host a conference call and webcast ... Tuesday, May 2, 2017 at 4:30 p.m. Eastern Time ...
(Date:4/18/2017)... DIEGO , April 18, 2017  Astute Medical, ... a case series to be presented at the 2017 ... which begins today and continues through April 22. Physicians ... IGFBP-7 , used to assess risk for acute kidney ... decompensated heart failure (ADHF). Elevated levels ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... ... As a former supermodel known for her timeless beauty, Joan Severance knows ... is that she put all the words in her new book, "Manifest Your Mate: ... and sparkling sense of humor have inspired her to write a book on how ...
(Date:4/24/2017)... ... 24, 2017 , ... Labs often perform the same operations ... operators and management to assess these processes with a critical eye—particularly in the ... , Created with the help of both internal and external process experts, ...
(Date:4/24/2017)... New York, NY (PRWEB) , ... April 24, ... ... students in 72 countries clearly shows that over the last decade, student well-being ... have ticked all the boxes of formal education, join the Islamic State to ...
(Date:4/24/2017)... ... ... “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues”: a guide to using ... Life Issues” is the creation of published author, Rachel Jamerson, writer of 25 years, ... USA, and former member of the American Association of Christian Counselors. Rachel studied ...
(Date:4/24/2017)... ... 2017 , ... Miami Periodontist and Dental Implant ... Foundation’s 2017 Symposium on Tissue Regeneration and Implant Dentistry held in Miami Beach ... Symposium at the Fontainebleau Hotel located in Miami Beach, FL. This annual symposium ...
Breaking Medicine News(10 mins):